Clinical trial
Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
NCT00227461 · Kessler Foundation, Other · Unknown status
Key facts
| NCT number | NCT00227461 |
|---|---|
| Title | Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. |
| Official title | Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. |
| Lead sponsor | Kessler Foundation, Other |
| Collaborators | UCB Pharma Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Aphasia, Stroke |
| Intervention type | Drug |
| Interventions | Wait first, then levetiracetam, Levetiracetam first, then wait |
| Enrollment | 50 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2021 |
| Completion | Dec 1, 2021 |
| First posted | Sep 28, 2005 |
| Last update posted | Feb 17, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: